Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q2 EPS by 320c

Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) reported Q2 EPS of $2.75, $3.20 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $542.71 million versus the consensus estimate of $127.9 million.

For earnings history and earnings-related data on Arrowhead Pharmaceuticals Inc. (ARWR) click here.

You May Also Be Interested In

• Gordon Haskett cuts TJX Companies rating to Accumulate
• Oppenheimer Reiterates Outperform Rating on salesforce.com (CRM)
• This name is "a later-cycle beneficiary of the AI spending cycle": Goldman